Probiotec Ltd
ASX:PBP

Watchlist Manager
Probiotec Ltd Logo
Probiotec Ltd
ASX:PBP
Watchlist
Price: 2.98 AUD Market Closed
Market Cap: 242.3m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PBP stock under the Base Case scenario is 5.79 AUD. Compared to the current market price of 2.98 AUD, Probiotec Ltd is Undervalued by 49%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PBP Relative Value
Base Case
5.79 AUD
Undervaluation 49%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.1
P/S
P/S
Price to Sales
1.1
vs History
33
vs Industry
68
Median 3Y
1
Median 5Y
1.1
Industry
2.4
Forward
1
More Details
27.9
P/E
P/E
Price to Earnings
27.9
vs History
30
vs Industry
16
Median 3Y
21.6
Median 5Y
26.8
Industry
21
Forward
16.4
More Details
15.5
P/OCF
P/OCF
Price to OCF
15.5
vs History
11
vs Industry
28
Median 3Y
12.4
Median 5Y
12.4
Industry
16.2
More Details
81.5
P/FCFE
P/FCFE
Price to FCFE
81.5
vs History
1
vs Industry
6
Median 3Y
47.8
Median 5Y
21.6
Industry
24
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
1
vs Industry
27
Median 3Y
2.5
Median 5Y
2.3
Industry
2
More Details
1.4
EV/S
EV/S
Enterprise Value to Sales
1.4
vs History
36
vs Industry
63
Median 3Y
1.3
Median 5Y
1.4
Industry
2.6
Forward
1.3
More Details
4.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.7
vs History
39
vs Industry
42
Median 3Y
4.4
Median 5Y
4.7
Industry
5.1
More Details
15.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.4
vs History
30
vs Industry
24
Median 3Y
14.5
Median 5Y
15.3
Industry
12.6
Forward
7.8
More Details
15.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15.4
vs History
30
vs Industry
28
Median 3Y
14.5
Median 5Y
15.3
Industry
16
Forward
12.3
More Details
19.7
EV/OCF
EV/OCF
Enterprise Value to OCF
19.7
vs History
11
vs Industry
22
Median 3Y
13.6
Median 5Y
14.4
Industry
14.4
More Details
64.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
64.2
vs History
1
vs Industry
7
Median 3Y
33.3
Median 5Y
31.8
Industry
17.6
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
1
vs Industry
40
Median 3Y
1.4
Median 5Y
1.4
Industry
1.8
More Details

Multiples Across Competitors

PBP Competitors Multiples
Probiotec Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Probiotec Ltd
ASX:PBP
242.3m AUD 1.1 27.9 15.4 15.4
US
Eli Lilly and Co
NYSE:LLY
687.3B USD 14 61.9 33.3 36.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
368.7B USD 4.1 16.9 12.4 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 6.8 19.7 13.6 15.7
CH
Roche Holding AG
SIX:ROG
207.5B CHF 3.4 25.1 9.4 11
CH
Novartis AG
SIX:NOVN
183.5B CHF 4.2 17.3 10.2 13.7
UK
AstraZeneca PLC
LSE:AZN
162.6B GBP 4 28.3 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
195.2B USD 3.1 11.2 8.4 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
134.2B USD 2.1 17 7.4 10.3
P/E Multiple
Earnings Growth PEG
AU
Probiotec Ltd
ASX:PBP
Average P/E: 25
27.9
20%
1.4
US
Eli Lilly and Co
NYSE:LLY
61.9
50%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.7
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.1
32%
0.8
CH
Novartis AG
SIX:NOVN
17.3
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.2
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Probiotec Ltd
ASX:PBP
Average EV/EBITDA: 395.3
15.4
35%
0.4
US
Eli Lilly and Co
NYSE:LLY
33.3
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.4
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Probiotec Ltd
ASX:PBP
Average EV/EBIT: 1 698.5
15.4
16%
1
US
Eli Lilly and Co
NYSE:LLY
36.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.7
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

See Also

Summary
PBP intrinsic value, competitors valuation, and company profile.
DCF Valuation
PBP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PBP stock valuation using valuation multiples.
Wall Street Estimates
PBP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PBP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 257,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.